GlycoMimetics has been granted a patent for methods and compositions using E-selectin antagonists for treating and preventing cancers, metastasis, and thrombus formation. The patent includes administering compounds as adjunct therapy to subjects undergoing chemotherapy or radiotherapy for leukemia, lymphoma, and myeloma. GlobalData’s report on GlycoMimetics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on GlycoMimetics, Cancer treatment biomarkers was a key innovation area identified from patents. GlycoMimetics's grant share as of May 2024 was 27%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of cancer using e-selectin antagonists
A recently granted patent (Publication Number: US11987598B2) discloses a method for treating cancer in a subject by administering a compound of Formula (I) or a pharmaceutically acceptable salt thereof. The treatment involves using the compound as an adjunct therapy alongside chemotherapy or radiotherapy. The cancer types targeted by this method include leukemia, lymphoma, and myeloma. The compound of Formula (I) can be administered in various forms, including as a pharmaceutically acceptable salt, with the sodium salt being a specific example mentioned in the claims.
Furthermore, the patent claims specify the specific types of leukemia, lymphoma, and myeloma that can be treated using this method, such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, and multiple myeloma (MM). The method also covers the administration of the compound of Formula (I) before, during, or after chemotherapy or radiotherapy, with specific mention of various chemotherapy agents like alkylating agents, antimetabolites, anthracyclines, plant alkaloids, and topoisomerase inhibitors. The claims provide a detailed framework for the administration of the compound and its salts in combination with existing cancer treatments, emphasizing the potential for improved therapeutic outcomes in cancer patients.
To know more about GlobalData’s detailed insights on GlycoMimetics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
